1. ALLA AKTIER
  2. NYHETER
  3. COMBIGENE

Combigene

Nyheter Combigene Nyheter alla bolag

CombiGene’s epilepsy project CG01 has been granted patent in two new countries

CombiGene AB (publ) ("CombiGene", the "Company") today announces that the patent offices in Australia and India have granted patent for the epilepsy project CG01. The approval strengthens the project, which CombiGene recently has regained the global rights to.

CG01 has previously been granted patents in the USA and Russia.

"The fact that CG01 has been granted patent in two new countries strengthens the project as we are putting together an attractive proposition for a potential partner," says Karin Agerman, Chief Scientific Officer at CombiGene. "Finding a new partner for the epilepsy project is of high priority for CombiGene this year," Karin concludes.

About the epilepsy project CG01
CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Attachments

PM Patent CG01 EN

Datum 2024-03-13, kl 09:30
Källa MFN
Bifogade filer
PM Patent CG01 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!